|
Synonyms: Dupixent® | REGN668 | SAR231893
dupilumab is an approved drug (EMA & FDA (2017))
Compound class:
Antibody
Comment: Dupilumab is fully human monoclonal antibody against the α subunit of the IL4 receptor.
Peptide sequences for this antibody are available from its IMGT/mAb-db record. Dupilumab was produced using Regeneron's genetically engineered VelocImmune® mice which have humanized immunoglobulin gene loci and produce human:mouse hybrid antibodies that can rapidly be converted to fully human antibodies [3]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Bioactivity Comments |
| Affinity data in the table below is taken from patent US7608693 [2], using antibody clone H4H098P as a representative example of the embodiment of the patent. The clone becoming dupilumab is not reported. |
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
